Ensysce Biosciences
ENSC
11 hedge funds and large institutions have $399K invested in Ensysce Biosciences in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
22% more funds holding
Funds holding: 9 → 11 (+2)
17.49% less ownership
Funds ownership: 25.05% → 7.56% (-17%)
56% less capital invested
Capital invested by funds: $903K → $399K (-$505K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$23.3K |
| 2 |
SS
SBI Securities
Tokyo,
Japan
|
+$5.35K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.13K |
| 4 |
Morgan Stanley
New York
|
+$866 |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
+$215 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$358K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$120K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.19K |
ENSC Hedge Fund Activity: Q2 2025 in Review
11 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q2 2025, worth a combined $399K — down 56% from $903K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ENSC positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $23.3K. The largest seller was Murchinson, exiting entirely with an estimated $358K sold.
- 11 institutional investors held Ensysce Biosciences (ENSC) as of Q2 2025, up from 9 in Q1 2025.
- Funds reported $399K of Ensysce Biosciences stock for Q2 2025, down 56% quarter-over-quarter.
- 4 funds opened new Ensysce Biosciences positions in Q2 2025 and 2 closed out, a net change of +2 holders.
- The largest Ensysce Biosciences buyer in Q2 2025 was Geode Capital Management, an estimated $23.3K added.
- The largest Ensysce Biosciences seller in Q2 2025 was Murchinson, an estimated $358K sold.
Based on aggregated 13F filings for Q2 2025.